These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22224832)

  • 1. Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan.
    Shaheen A; Najmi MH; Saeed W; Farooqi ZU
    Scand J Infect Dis; 2012 Jun; 44(6):459-64. PubMed ID: 22224832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children.
    Donald PR; Maritz JS; Diacon AH
    Tuberculosis (Edinb); 2011 May; 91(3):196-207. PubMed ID: 21429802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RMP exposure is lower in HIV-infected TB patients receiving intermittent than daily anti-tuberculosis treatment.
    Hemanth Kumar AK; Narendran G; Kumar RS; Ramachandran G; Sekar L; Raja K; Swaminathan S
    Int J Tuberc Lung Dis; 2015 Jul; 19(7):805-7. PubMed ID: 26056105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampicin serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme, India, 2009.
    Arya A; Roy V; Lomash A; Kapoor S; Khanna A; Rangari G
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):440-5. PubMed ID: 25860000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of primary multidrug resistance to anti-tuberculosis drugs in Pakistan.
    Javaid A; Hasan R; Zafar A; Ghafoor A; Pathan AJ; Rab A; Sadiq A; Akram CM; Burki I; Shah K; Ansari M; Rizvi N; Khan SU; Awan SR; Syed ZA; Iqbal ZH; Shaheen Z; ur Rehman N
    Int J Tuberc Lung Dis; 2008 Mar; 12(3):326-31. PubMed ID: 18284840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
    Avachat AM; Bhise SB
    Pharm Dev Technol; 2011 Apr; 16(2):127-36. PubMed ID: 20105081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.
    Nijland HM; Ruslami R; Stalenhoef JE; Nelwan EJ; Alisjahbana B; Nelwan RH; van der Ven AJ; Danusantoso H; Aarnoutse RE; van Crevel R
    Clin Infect Dis; 2006 Oct; 43(7):848-54. PubMed ID: 16941365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.
    Kumar AKH; Chandrasekaran V; Kumar AK; Kawaskar M; Lavanya J; Swaminathan S; Ramachandran G
    Indian J Med Res; 2017 Apr; 145(4):530-535. PubMed ID: 28862186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients.
    Babalık A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildiz L; Çarpaner E
    Int J Tuberc Lung Dis; 2013 Nov; 17(11):1442-7. PubMed ID: 24125448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis.
    Peloquin CA; Maslow JN; Mikota SK; Forrest A; Dunker F; Isaza R; Peddie LR; Peddie J; Zhu M
    J Vet Pharmacol Ther; 2006 Dec; 29(6):581-5. PubMed ID: 17083464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.